In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...